Skip to main content
Caplight Logo









Vigeo Therapeutics

Vigeo Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://vigeotx.com/

Last Round

Series C

Mar 10, 2021

Total Funding Raised

$62.58M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Vigeo Therapeutics is a biotechnology company that develops novel therapeutics for the treatment of cancer and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalimmunotherapypeptide therapeuticoncologytumor microenvironmentdrug discoveryclinical trialsbiotechsolid tumorsinflammatory diseasedrug developmentthrombospondin-1TSP-1cancer researchclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vigeo Therapeutics Comparables

Compare Vigeo Therapeutics with similar companies based on industry and business-model similarity.

Vigeo Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sapience Therapeutics
80%
Bexion Pharmaceuticals
78%
Imvax
77%

Vigeo Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMar 10, 2021
Series BDec 19, 2018
Series ANov 15, 2017
Series AJun 12, 2015

Vigeo Therapeutics Investors

Notable investors and investment history

Vigeo Therapeutics investors
InvestorRounds
Morningside VenturesSeries A, Series B
Morningside GroupSeries B, Series C, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 9, 180% of current headcount.

  • Mar 25, 2021

    Raised $8 million in debt financing.

Vigeo Therapeutics Filings

Explore SEC and related filing metadata, where available.

Vigeo Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Vigeo Therapeutics's valuation, stock price, and market status.

Is Vigeo Therapeutics a public or private company?

Vigeo Therapeutics is a private company.

What is the current stock price of Vigeo Therapeutics?

Vigeo Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Vigeo Therapeutics worth (valuation)?

Valuation information for Vigeo Therapeutics is not publicly available.

Can I buy Vigeo Therapeutics stock?

Vigeo Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Vigeo Therapeutics's last funding round?

Vigeo Therapeutics's most recent funding round was Debt on March 25, 2021.

Who are the main investors in Vigeo Therapeutics?

Key investors in Vigeo Therapeutics include Morningside Ventures, Morningside Group.

Will Vigeo Therapeutics IPO soon?

No public IPO plans have been announced for Vigeo Therapeutics.

How can I track Vigeo Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vigeo Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range6
Year Founded2011
Last FundingMar 10, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?